EVIDENCE PROFILE / PUBLISHED
Gonadorelin
Gonadorelin is synthetic GnRH, a decapeptide that releases LH and FSH. In Canada its human products are cancelled or dormant and marketed entries are veterinary. The only human evidence reviewed is one retrospective cohort of pulsatile GnRH ovulation induction in women with functional hypothalamic amenorrhea.
Evidence at a glance
- Human
- LimitedOne single-centre retrospective cohort (66 women, one diagnosis) read in full; no randomized trial.
- Animal/cell
- Not rated
- Approved medicine
- Not rated
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. This concise profile was researched from primary and regulatory records; supplier listings were used only to find the name.
Identity
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH, also called LHRH), the decapeptide 5-oxoPro-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (C55H75N17O13; PubChem CID 638793). A proposed amino-acid sequence for the porcine LH- and FSH-releasing hormone was published in 1971. Acetate, hydrochloride and diacetate tetrahydrate salts differ, and substituted analogues such as the gonadorelin [6-D-Phe] acetate listed by Health Canada are separate molecules.
Biological mechanism or research interest
Gonadorelin acts at the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The U.S. veterinary label describes synthetic gonadorelin as physiologically and chemically identical to the endogenous bovine hypothalamic releasing factor. Human research reviewed here concerns pulsatile GnRH delivery to induce ovulation in women with functional hypothalamic amenorrhea.
Verified approved human uses
Health Canada's Drug Product Database lists its human gonadorelin products (Factrel, Relisorm, Lutrepulse) as cancelled post market or dormant; the entries returned by the gonadorelin search and listed as marketed are all veterinary products, one of which (GONAVET) is a [6-D-Phe] analogue. In the U.S., Cystorelin (gonadorelin diacetate tetrahydrate) is a prescription veterinary drug for dairy and beef cattle under NADA 098-379 and is labeled not for use in humans. None of these records validates a catalogue material.
Investigational human evidence
A 2022 single-centre retrospective Swiss cohort of 66 women with functional hypothalamic amenorrhea (82 treatments, 212 cycles) treated with pulsatile GnRH therapy (Ferring's Zyklomat Pulse from 1996 to 2010, then the Lutrepulse system with Lutrelef from 2011) reported a 65.9% live birth rate per treatment and one twin pregnancy; a 96% ovulation rate per cycle was reported for the cycles with data available from 2014 to 2020. The paper does not use the name gonadorelin or name a salt, had no randomized comparator, and does not address men or other uses.
Popular claims versus demonstrated findings
Claims that a catalogue vial supports testosterone, male fertility or general hormone optimization are not demonstrated in the sources reviewed. Those sources cover cattle reproduction under a veterinary label and supervised ovulation induction in women with one specific diagnosis. None of them studied men, testosterone outcomes or healthy adults, so these uses remain outside the evidence summarised here.
Human versus animal or cell evidence
In U.S. multi-site field studies summarized on the veterinary label, gonadorelin used with cloprostenol raised pregnancy rates to fixed-time insemination compared with water given in place of gonadorelin (33.4% vs 13.6% in lactating dairy cows; 21.7% vs 7.4% in beef cows). The label also summarizes acute and short-term toxicology in mice, rats and dogs, and reports no embryotoxic or teratogenic effects in pregnant rats and rabbits at the tested exposures. These animal results do not establish human safety.
Limitations and known risks
The U.S. veterinary label states "Not for use in humans." The human cohort reported no severe adverse events but was retrospective, single-centre and limited to one diagnosis under specialist care, so it does not describe risks in other populations. Health Canada lists none of the Canadian human products as marketed. The catalogue material's identity, salt, purity, sterility and stability are unverified.
